0.005% by weight to approximately 10% by weight, based on the total weight of the pharmaceutical aerosol foam composition.

6. (Amended) A pharmaceutical aerosol foam composition according to Claim 5, wherein the occlusive agent is petrolatum.

7. (Amended) A pharmaceutical aerosol foam composition according to Claim 1, wherein the occlusive agent is present in an amount of approximately 55% by weight or less, based on the total weight of the composition.

18. (Amended) A pharmaceutical aerosol dispenser comprising:

a pharmaceutical aerosol foam composition including

an effective amount of a pharmaceutically active ingredient

an occlusive agent;

an aqueous solvent;

an organic cosolvent.

the pharmaceutically active ingredient being insoluble in both water and the occlusive agent;

the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.

Please add new claims ~~19~~-32 as follows:

~~19~~. A pharmaceutical aerosol foam composition comprising:

an effective amount of a pharmaceutically active ingredient;

petrolatum in an amount of approximately 55% by weight or less, based on the total weight of the composition;

an aqueous solvent; and

an organic cosolvent,

the pharmaceutically active ingredient being insoluble in both water and petrolatum.

20. The pharmaceutical aerosol foam composition according to claim 19, wherein the occlusive agent is present in an amount of approximately 10 to 50% by weight, based on the total weight of the composition.

21. The pharmaceutical aerosol foam composition according to claim 19, wherein the water insoluble pharmaceutically active ingredient is selected from one or more of the group consisting of an analgesic, anti-inflammatory agent, antifungal, antibacterial, anaesthetic, xanthine, sex hormone, antiviral, antipruritic, antihistamine or corticosteriod.

22. The pharmaceutical aerosol foam composition according to claim 21, wherein the pharmaceutically active ingredient is a corticosteroid selected from one or more of the group consisting of betamethasone valerate and clobetasol propionate.

23. The pharmaceutical aerosol foam composition according to claim 19, wherein the pharmaceutically active ingredient is present in amounts of from approximately 0.005% by weight to approximately 10% by weight, based on the total weight of the pharmaceutical aerosol foam composition.

24. The pharmaceutical aerosol foam composition according to claim 19, further including an effective amount of an emulsifier and/or surfactant.

25. The pharmaceutical aerosol foam composition according to claim 24, wherein the emulsifier or surfactant is selected from any one or more of the group consisting of non-ionic, cationic or anionic surfactants, fatty alcohols, fatty acids and fatty acid salts thereof.

26. The pharmaceutical aerosol foam composition according to claim 25, wherein the emulsifier includes a mixture of sorbitan monostearate and polysorbate 60.

Rule 1.129

28 27. The pharmaceutical aerosol foam composition according to claim 25 ~~24~~, wherein the surfactant component is present in an amount of from approximately 1 to 15% by weight, based on the total weight of the composition.

29 28. The pharmaceutical aerosol foam composition according to claim 20 ~~19~~, wherein the aqueous solvent is present in an amount of from approximately 25 to 95% by weight, based on the total weight of the composition.

30 29. The pharmaceutical aerosol foam composition according to claim 20 ~~19~~, wherein the organic cosolvent is present in an amount of from approximately 0.25% by weight to 50% by weight, based on the total weight of the composition.

B4

31 30. The pharmaceutical aerosol foam composition according to claim 30 ~~29~~, wherein the organic cosolvent is an alkyl benzoate.

32 31. The pharmaceutical aerosol foam composition according to claim 20 ~~19~~, further including an effective amount of an aerosol propellant.

33 32. The pharmaceutical aerosol foam composition according to claim 32 ~~31~~, wherein the aerosol propellant is a hydrocarbon and is present in an amount of from approximately 2.5 to 20% by weight, based on the total weight of the composition.

ADD C3

REMARKS

Applicants' undersigned representative wishes to thank Examiners Dudash and Ostrup for their time and helpful suggestions in the telephone interview held on December 3, 2001, during which the pending claims and prior art were discussed. Claims 1-18 were originally pending. By virtue of this response, claims 1, 3, 4, 6, 7 and 18 have been amended, and new claims 19-32 have been added.